| Literature DB >> 27342785 |
Martin Büchsel1, Lars Pletschen2, Michael Fleiner2, Georg Häcker3, Annerose Serr3.
Abstract
Mycoplasma salivarium is a rare agent of septic arthritis in immunocompromised patients. We report a case of septic arthritis due to Mycoplasma salivarium in a patient with B-cell chronic lymphocytic leukemia who underwent chemotherapy with rituximab and bendamustin. Therapy of arthritis due to Mycoplasma salivarium is difficult because there are almost no susceptibility data available. The present case illustrates that antimicrobial susceptibility of Mycoplasma strains is not necessarily predictable and that antibiotic therapy should therefore be guided by in vitro susceptibility testing.Entities:
Keywords: B-CLL; Mycoplasma salivarium; Rituximab; Septic arthritis; Susceptibility
Mesh:
Substances:
Year: 2016 PMID: 27342785 DOI: 10.1016/j.diagmicrobio.2016.05.018
Source DB: PubMed Journal: Diagn Microbiol Infect Dis ISSN: 0732-8893 Impact factor: 2.803